Finland
· Delayed Price · Currency is EUR Herantis Pharma Oyj Statistics
Total Valuation
Herantis Pharma Oyj has a market cap or net worth of EUR 29.94 million. The enterprise value is 26.48 million.
| Market Cap | 29.94M |
| Enterprise Value | 26.48M |
Important Dates
The next estimated earnings date is Friday, September 13, 2024.
| Earnings Date | Sep 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Herantis Pharma Oyj has 20.16 million shares outstanding. The number of shares has increased by 10.24% in one year.
| Shares Outstanding | 20.16M |
| Shares Change (YoY) | +10.24% |
| Shares Change (QoQ) | +15.35% |
| Owned by Insiders (%) | 9.98% |
| Owned by Institutions (%) | 58.13% |
| Float | 14.17M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 14.68 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -43.26 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.30, with a Debt / Equity ratio of 1.47.
| Current Ratio | 2.30 |
| Quick Ratio | 2.28 |
| Debt / Equity | 1.47 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -661.79% and return on invested capital (ROIC) is -5.09%.
| Return on Equity (ROE) | -661.79% |
| Return on Assets (ROA) | -2.75% |
| Return on Capital (ROIC) | -5.09% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -55,651 |
| Employee Count | 10 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -6.60% in the last 52 weeks. The beta is 0.35, so Herantis Pharma Oyj's price volatility has been lower than the market average.
| Beta (5Y) | 0.35 |
| 52-Week Price Change | -6.60% |
| 50-Day Moving Average | 1.53 |
| 200-Day Moving Average | 1.51 |
| Relative Strength Index (RSI) | 47.15 |
| Average Volume (20 Days) | 6,651 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -193,631 |
| Pretax Income | -612,160 |
| Net Income | -612,160 |
| EBITDA | n/a |
| EBIT | -193,631 |
| Earnings Per Share (EPS) | -0.03 |
Balance Sheet
The company has 3.49 million in cash and 30,000 in debt, giving a net cash position of 3.46 million or 0.17 per share.
| Cash & Cash Equivalents | 3.49M |
| Total Debt | 30,000 |
| Net Cash | 3.46M |
| Net Cash Per Share | 0.17 |
| Equity (Book Value) | 2.04M |
| Book Value Per Share | 0.10 |
| Working Capital | 2.07M |
Cash Flow
| Operating Cash Flow | -5.95M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Herantis Pharma Oyj does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.24% |
| Shareholder Yield | -10.24% |
| Earnings Yield | -2.19% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |